MRI Scans May Predict Response to Antipsychotics
the Psychiatry Advisor take:
Functional magnetic resonance imaging (fMRI) scans of the brain may make it possible to predict a patient’s response to antipsychotic medications.
Anil Malhotra, MD, Zucker Hillside Hospital, Glen Oaks, N.Y., and colleagues took fMRIs of 41 first-episode schizophrenia patients to develop a prognostic index in a discovery cohort. The group received a resting-state fMRI after starting randomized treatment with a second-generation anti-psychotic.
The results were compared against FMRIs taken from 40 newly hospitalized chronic patients with acute psychosis. Clinical response was calculated that required sustained improvement over two consecutive study visits. Response was entered into a survival analysis, and Cox regression was applied to the functional connectivity data.
A striatal connectivity index was created, comprising functional connections of the striatum — an area of the brain that tends to be abnormal in those suffering from psychosis — that successfully predicted treatment response, the researchers reported in The American Journal of Psychiatry.
When this index was used to confirm their results in the chronic group, they found that treatment outcome could be predicted in this cohort as well.
“This study is the first to report a predictive fMRI-derived measure validated in an independent study group of patients treated with antipsychotics,” Deepak Sarpal, MD, a study author said in a statement. “The results we found from this study open the door for contemporary ‘precision medicine’ approaches to psychiatry, and more specifically, the use of fMRI scans as important players in the treatment of psychiatric disorders.”
Results open the door for "precision medicine" approach to psychiatry.
Investigators at The Feinstein Institute for Medical Research have discovered that brain scans can be used to predict patients' response to antipsychotic drug treatment. The findings are published online in the latest issue of The American Journal of Psychiatry.
Psychotic disorders, such as schizophrenia and bipolar disorder, are characterized by delusions, hallucinations, and disorganized thoughts and behavior. They are estimated to occur in up to three percent of the population and are a leading cause for disability worldwide. Psychotic episodes are currently treated with antipsychotic drugs, but this treatment is given without guidance from lab tests or brain scans, such as functional magnetic resonance imaging or functional MRI (fMRI).
Doctors often use "trial-and-error" when choosing treatment for psychotic disorders, without knowing if patients will respond well. This lack of knowledge places a large burden on not only patients and their families, but also healthcare professionals and healthcare systems.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Etiology of Schizophrenia: Strong Association With Certain Rare Copy Number Variants
- Long-Term Lithium Use: More Evidence Needed to Associate With Cancer Risk
- FDA to Review Lumateperone for Treatment of Schizophrenia
- AMA Survey Collects Advice for Physicians Approaching Retirement
- Revised Children's Anxiety and Depression Scales Reliable Measurement Tool for Adults
- Cannabis Use, Cannabis Use Disorder Linked to Psychotic, Depressive Symptoms
- Abstinence From Regular Cannabis Use Improves Memory Among Adolescents, Young Adults
- Group Cognitive Behavioral Therapy Is Effective Treatment for Adolescent Anxiety
- Association Between Opioid and Benzodiazepine Misuse and Suicidal Ideation
- The Intersection of Eating and Alcohol Disorders: Detecting and Managing "Drunkorexia"
- Cognition, Depression, and Limited Functioning Linked in Middle Age
- Coping With Challenges When Working the Holidays
- Lithium Preferred Method of Maintenance Monotherapy in Older Adults With Bipolar Disorder
- Hypobetalipoproteinemia Associated With Aggression and Schizophrenia
- AMA Code of Medical Ethics Guides Physicians in Fighting Harmful Online Health Information